At the end of treatment, willingness to continue therapy was also higher with the injector, at 50.7% versus 31.4%. A separate substudy evaluated administration at home by a health care provider beginning at cycle 6. All 148 analyzed home injections were completed, with one grade 1 injection-site reaction.2
The findings have implications for infusion capacity and patient convenience. For pharmacists, they highlight the importance of delivery preferences alongside the clinical performance of a chronic regimen, particularly when evaluating opportunities to reduce the time patients spend receiving treatment.2
3. Isatuximab–Iberdomide Maintenance Deepens Responses in MIDAS
Among 219 patients who began maintenance, 55 converted to MRD negativity at the 10⁻⁶ threshold during the first year. MRD-negative rates increased from 40% to 58% in the single-transplant arm and from 32% to 48% in the tandem-transplant arm.3
The results also underscore the monitoring burden: grade 3 or higher neutropenia occurred in 42% of patients and infections in 18%. These findings place blood count surveillance and infection prevention alongside response assessment. Because both transplant groups received the same maintenance regimen, the analysis does not establish superiority over an alternative maintenance treatment.3
4. Linvoseltamab Findings Renew the Debate About Earlier Treatment
The
Safety remains central to interpreting earlier intervention. Infections occurred in 92% of patients, including grade 3 infections in 19%, despite supportive care that included immunoglobulin replacement and infection prophylaxis.4
Confirmatory evidence could affect treatment eligibility and payer policies. For pharmacists, the results raise questions about balancing deep responses with the burden of treating patients before active disease develops. The findings do not establish linvoseltamab as routine therapy in this setting, and longer-term evidence remains important to assessing its clinical value.4
5. Ramantamig Interview Examines Response Durability and Outpatient Care
In a
Matous also reviewed an expanded 30-patient outpatient cohort using prophylactic tocilizumab before step-up dosing. His discussion addresses cytokine release syndrome management and the practical requirements for moving treatment into community settings.5
The interview connects efficacy findings with operational decisions, including infection prophylaxis and treatment-day scheduling. It offers pharmacists a closer look at the supportive-care planning required as investigational T-cell–engaging therapies are evaluated for broader delivery.5
